An observational study in Temporomandibular Disorders (TMD), Muscle Pain and TMJ Pain, sponsored by Wroclaw Medical University. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Wroclaw Medical University · Observational
Among 25 studies in Temporomandibular Joint Disorders with a site in Poland — 7 open to participants now, 7 under way, 1 of them phase 3. Temporomandibular Joint Disorders · Poland.
Among the 25 studies in Temporomandibular Joint Disorders with a site in Poland, this one is the 7th largest by planned enrollment of the 10 observational ones, is one of 2 that started in 2026, is one of 10 observational ones, and was the 24th registered.
591 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
This study's planned enrollment of 68 is below the median of 91 across 165 observational studies indexed under Temporomandibular Joint Disorders.
Browse Temporomandibular Joint Disorders studies →7 of the 25 studies in Temporomandibular Joint Disorders with a site in Poland are open now, in 12 countries. Each count lists the studies.
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →25 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2026.
Median enrollment 51 across the 15 interventional studies, 80 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
None of the 25 has an industry lead sponsor. The 10 most frequent:
Wroclaw Medical University is the lead sponsor of 99 studies on the registry; 29 are open to participants now.
Wroclaw Medical University has 7 studies filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Temporomandibular Joint Disorders with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05214924Phase 3Wroclaw Medical UniversityEffectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management | 2026-12-31 |
| NCT04214561Wroclaw Medical UniversityRelationship Between Selected Parameters and Bruxism | 2026-12 |
| NCT03083405Wroclaw Medical UniversitySelected Disorders and Sleep Bruxism | 2026-12 |
Among the 25 studies in Temporomandibular Joint Disorders with a site in Poland, from their registry updates:
The aim of the research is the laboratory assessment of the content as well as the regenerative and anti-inflammatory potential of autologous exosomes (EXO) from platelet-rich plasma (PRP), as well as their comparison with other autologous products used in intra-articular injections, namely platelet-rich plasma and platelet-rich fibrin (PRF).
The material for the research will be obtained from patients of the Temporomandibular Joint Dysfunction Clinic at the University Dental Center in Wrocław with chronic pain of the temporomandibular joints (TMJ) and/or masticatory muscles and/or chronic disturbances in temporomandibular joint mobility, as well as from healthy individuals.
In the subsequent stages, the biological material will be analyzed under laboratory conditions to compare the composition and biological properties of PRP, PRF and EXO.
The research focuses on the laboratory assessment of the content and the regenerative and anti-inflammatory potential of autologous exosomes from platelet-rich plasma, as well as their comparison with other autologous products used in intra-articular injections (PRP, PRF).
The work will include:
The implementation of the project will constitute a significant contribution to the development of knowledge about the molecular mechanisms of the regenerative action of plasma-derived exosomes. The obtained results will allow a better understanding of the action of the evaluated systems, and, consequently, better effects of intra-articular injections through the optimal selection of autologous injection material. It should be emphasized that autologous injection therapies are safe for patients and are associated with the lowest risk of complications among all injection therapies used in the treatment of TMJ disorders, which is why their precise investigation is very important.
participants with chronic pain of the temporomandibular joints and/or masticatory muscles and/or chronic disorder of temporomandibular joint mobility
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic temporomandibular joint pain and/or masticatory muscle pain and/or chronic temporomandibular joint movement disorders
Diagnostic Test: Laboratory analysis of the content and biological activity of PRP, PRF, and exosomes obtained from blood samples
Healthy participants without a diagnosis of chronic temporomandibular joint pain and/or masticatory muscle pain and/or chronic temporomandibular joint movement disorders
Diagnostic Test: Laboratory analysis of the content and biological activity of PRP, PRF, and exosomes obtained from blood samples
Laboratory analysis include in vitro tests aimed to: (1) evaluation of the size and concentration of exosomes, (2) the measurement of the level of cytokines and growth factors in the samples of PRP, PRF and EXO, (3) comparison of the impact of exosomes, PRF and PRP (from the study and control groups) on the proliferation and migration of human chondrocytes and fibroblasts.
Comparison of the number and size of exosomes obtained from the study and control groups
Time frame: 04.2026 - 12.2027
Comparison of the level of cytokines and growth factors in exosomes, PRF and PRP samples obtained from the study and control groups
Time frame: 04.2026 - 12.2027
Comparison of the impact of exosomes, PRF and PRP (from the study and control groups) on the proliferation and migration of human chondrocytes and fibroblasts
Time frame: 04.2026 - 12.2027
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →
Wroclaw Medical University